Skip to Content


In the US, Cladribine (cladribine systemic) is a member of the drug class antimetabolites and is used to treat Hairy Cell Leukemia and Multiple Sclerosis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Cytostatic agent: Antimetabolite

Chemical Name


Foreign Names

  • Cladribinum (Latin)
  • Cladribin (German)
  • Cladribine (French)
  • Cladribina (Spanish)

Generic Names

  • Cladribine (OS: BAN, DCF, USAN, JAN)
  • CdA (IS)
  • Chlorodeoxyadenosine (IS)
  • RWJ 26251 (IS)
  • RWJ 26251-000 (IS)
  • Cladribine (PH: BP 2018, Ph. Eur. 9, USP 41)
  • Cladribinum (PH: Ph. Eur. 9)

Brand Names

  • Ai Bo Ding
    Hisun Pfizer Pharmaceuticals, China
  • Biodribin
    Inst. Biotechn. i Antybiotykow, Poland
  • Cladribine Baxter
    Baxter, New Zealand
  • Cladribine Fresenius Kabi
    Fresenius Kabi Canada, Canada
  • Cladribine Mylan
    Mylan, Poland
  • Intocel
    Sidus, Argentina
  • Leustat
    Janssen Cilag, Argentina; Janssen-Cilag, Egypt; Janssen-Cilag, United Kingdom; Janssen-Cilag, Lebanon
  • Leustatin
    Cilag, Hong Kong; Janssen, Lebanon; Janssen, New Zealand; Janssen, Taiwan; Janssen, Venezuela; Janssen, South Africa; Janssen Pharmaceutical, Japan; Janssen-Cilag, Australia; Janssen-Cilag, Belgium; Janssen-Cilag, Brazil; Janssen-Cilag, Germany; Janssen-Cilag, Spain; Janssen-Cilag, Greece; Janssen-Cilag, Italy; Janssen-Cilag, Netherlands; Janssen-Cilag, Portugal; Janssen-Cilag, Uruguay
  • Leustatin 1mg/ml
    Janssen, Luxembourg
  • Leustatine
    Janssen-Cilag, France
  • Litak
    Aspen, New Zealand; Biotefar, Peru; Key Oncologics, South Africa; Lipomed, Belgium; Lipomed, Cyprus; Lipomed, Czech Republic; Lipomed, Germany; Lipomed, Denmark; Lipomed, Estonia; Lipomed, Spain; Lipomed, France; Lipomed, United Kingdom; Lipomed, Lithuania; Lipomed, Macedonia; Lipomed, Netherlands; Lipomed, Norway; Lipomed, Poland; Lipomed, Romania; Lipomed, Serbia; Lipomed, Sweden; Lipomed, Taiwan; Lipomed AG, Tunisia; Medifront, Finland; Medis Adria, Croatia (Hrvatska); Orphan, Australia
  • Litak 10
    Lipomed, Israel
  • Litak 10mg/5ml
    Lipomed, Switzerland
  • Litak 2mg/ml
    Lipomed, Austria; Lipomed, Hungary; Lipomed, Luxembourg
  • Mavenclad
    Merck, Finland; Merck, Greece; Merck, Norway; Merck, Sweden; Merck KGaA, Portugal; Merck Serono, Australia; Merck Serono, Belgium; Merck Serono, United Kingdom; Merck Serono, Ireland; Merck Serono, Netherlands; Merck Serono, Slovenia; MSD, Denmark
  • Mavenclad 10mg
    Merck, Luxembourg
  • Ocladra
    Biem, Turkey


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.